Viking Therapeutics Inc.

VKTX

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 293,790Value: $21.0M

# Signal Note: Driehaus Capital Initiates $21M VKTX Position **Significance:** Driehaus's entry into Viking's obesity pipeline suggests conviction in VK2735, a dual GLP-1/GCG agonist in Phase 2b development that could compete in the multi-billion-dollar weight-loss market. The $21M stake (0.9% of shares outstanding) represents meaningful conviction from a growth-focused allocator, likely positioned ahead of Phase 2b efficacy readout (expected mid-2025) that will determine clinical differentiation versus established GLP-1 competitors like Novo/Eli Lilly.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: